Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

FORTE BIOSCIENCES, INC.

(FBRX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/19/2021 07/20/2021 07/21/2021 07/22/2021 07/23/2021 Date
32.92(c) 32.98(c) 36.67(c) 32.68(c) 31.2686 Last
197 850 185 894 183 742 718 769 64 978 Volume
+6.02% +0.18% +11.19% -10.88% -4.32% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -22,6 M - -
Net Debt 2021 96,0 M - -
P/E ratio 2021 -20,7x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -35,5 M - -
Net Debt 2022 147 M - -
P/E ratio 2022 -12,6x
Yield 2022 -
Capitalization 442 M 442 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 9
Free-Float 72,3%
More Financials
Company
Forte Biosciences, Inc., formerly Tocagen Inc., is a clinical-stage biopharmaceutical company. The Company is focused on clinical program and developing a live biotherapeutic for the treatment of inflammatory skin diseases, particularly for pediatric atopic dermatitis patients. It provides FB-401, which is a live biotherapeutic for the treatment of inflammatory skin diseases. FB-401 has completed Phase I/II a... 
More about the company
Ratings of Forte Biosciences, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D+
More Ratings
All news about FORTE BIOSCIENCES, INC.
07/12FORTE BIOSCIENCES, INC. : Reports Inducement Grants Under Nasdaq Listing Rules
BU
07/01FORTE BIOSCIENCES, INC. : Reports Inducement Grants Under Nasdaq Listing Rules
BU
06/04FORTE BIOSCIENCES, INC. : Change in Directors or Principal Officers, Submission ..
AQ
05/14FORTE BIOSCIENCES : B. Riley Starts Forte Biosciences at Buy with $73 PT, Says F..
MT
05/12FORTE BIOSCIENCES : ANNOUNCES FIRST QUARTER 2021 RESULTS AND PROVIDES A GENERAL ..
PU
05/10FORTE BIOSCIENCES, INC. : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
AQ
05/10FORTE BIOSCIENCES, INC. : Financial Statements and Exhibits, Regulation FD Discl..
AQ
05/10FORTE BIOSCIENCES, INC. : Announces First Quarter 2021 Results and Provides a Ge..
BU
05/10Forte Biosciences, Inc. Announces Earnings Results for the First Quarter Ende..
CI
05/10Forte Biosciences, Inc. Expects to Report the Topline Results from That Trial..
CI
05/03FORTE BIOSCIENCES, INC. : to Announce First Quarter 2021 Results and Provide a G..
BU
03/26FORTE BIOSCIENCES : Citigroup Starts Forte Biosciences at Buy With $75 Price Tar..
MT
03/24FORTE BIOSCIENCES : Q4 Loss Narrows Amid Higher Spending
MT
03/24FORTE BIOSCIENCES, INC. : Announces 4Q and Full Year 2020 Results and Provides a..
BU
03/24FORTE BIOSCIENCES, INC. : Financial Statements and Exhibits, Regulation FD Discl..
AQ
More news
News in other languages on FORTE BIOSCIENCES, INC.

- No features available -

More news
Analyst Recommendations on FORTE BIOSCIENCES, INC.
More recommendations
Chart FORTE BIOSCIENCES, INC.
Duration : Period :
Forte Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FORTE BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 32,68 $
Average target price 86,00 $
Spread / Average Target 163%
EPS Revisions
Managers and Directors
Paul A. Wagner Chairman, President & Chief Executive Officer
Anthony A. Riley Chief Financial Officer
Daniel J. Burge Chief Medical Officer & Head-Clinical Development
Lawrence F. Eichenfield Independent Director
Steven Andrew Kornfeld Independent Director
Sector and Competitors
1st jan.Capi. (M$)
FORTE BIOSCIENCES, INC.-10.24%482
GILEAD SCIENCES, INC.17.83%85 134
WUXI APPTEC CO., LTD.44.25%71 226
REGENERON PHARMACEUTICALS21.48%57 013
BIONTECH SE244.68%55 555
VERTEX PHARMACEUTICALS-17.06%50 308